{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T23:56:17Z","timestamp":1785455777244,"version":"3.56.0"},"reference-count":40,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100017655","name":"Incyte","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017655","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Science"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    We conducted a phase 1b study evaluating safety and tolerability of tafasitamab, a CD19\u2010targeting immunotherapy, in Japanese patients with B\u2010cell non\u2010Hodgkin lymphoma (NHL). Eligible patients were \u2265\u200918\u2009years old with relapsed\/refractory (R\/R) B\u2010cell NHL (Group 1), R\/R diffuse large B\u2010cell lymphoma (DLBCL; Groups 3 and 4), or untreated DLBCL (Group 5). Patients received tafasitamab starting at 12\u2009mg\/kg qw (Group 1,\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u20096), tafasitamab + lenalidomide starting at 25\u2009mg qd for \u2264\u200912\u2009cycles (Group 3,\n                    <jats:italic>n\u2009=<\/jats:italic>\n                    \u20096), tafasitamab + parsaclisib starting at 20\u2009mg qd (Days 1\u201356) then 2.5\u2009mg qd (Group 4,\n                    <jats:italic>n\u2009=<\/jats:italic>\n                    \u20096), or tafasitamab + lenalidomide combined with R\u2010CHOP for \u2264\u20096\u2009cycles (Group 5,\n                    <jats:italic>n\u2009=<\/jats:italic>\n                    \u20096). Primary objective was safety and tolerability of tafasitamab alone and in combination; exploratory objectives included efficacy. At data cutoff (August 31, 2023), 24 patients were treated. All patients experienced treatment\u2010emergent adverse events (TEAEs). Two patients experienced a dose\u2010limiting toxicity; liver disorder (grade 4) considered related to lenalidomide (Group 3,\n                    <jats:italic>n\u2009=<\/jats:italic>\n                    \u20091), and febrile neutropenia (grade 3) considered related to lenalidomide and R\u2010CHOP (Group 5,\n                    <jats:italic>n\u2009=<\/jats:italic>\n                    \u20091). Most common TEAEs across groups were hematological and included neutropenia, leukopenia, thrombocytopenia, and anemia; most common non\u2010hematological TEAEs included increased alanine aminotransferase, increased aspartate aminotransferase, diarrhea, nausea, constipation, and infusion\u2010related reactions. No serious tafasitamab treatment\u2010related or fatal TEAEs were observed. Results suggest tafasitamab alone or in combination demonstrates a manageable safety profile in Japanese patients with B\u2010cell NHL. Preliminary efficacy results from the study are reported. However, results should be interpreted with caution due to the small sample size, with further studies warranted to confirm these findings.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Trial Registration:<\/jats:bold>\n                    NCT04661007; jRCT2031200357\n                  <\/jats:p>","DOI":"10.1111\/cas.70306","type":"journal-article","created":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T17:46:35Z","timestamp":1769017595000},"page":"1093-1105","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Tafasitamab as Monotherapy or in Combination in Japanese Patients With B\u2010Cell Non\u2010Hodgkin Lymphoma: Results From the Phase 1b J\u2010\n                    <scp>MIND<\/scp>\n                    Study"],"prefix":"10.1111","volume":"117","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9129-8057","authenticated-orcid":false,"given":"Koji","family":"Izutsu","sequence":"first","affiliation":[{"name":"National Cancer Center Hospital  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2682-2179","authenticated-orcid":false,"given":"Noriko","family":"Fukuhara","sequence":"additional","affiliation":[{"name":"Tohoku University Hospital  Sendai Miyagi Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichiro","family":"Yuda","sequence":"additional","affiliation":[{"name":"National Cancer Center Hospital East  Chiba Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youko","family":"Suehiro","sequence":"additional","affiliation":[{"name":"National Hospital Organization Kyushu Cancer Center  Fukuoka City Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeru","family":"Kusumoto","sequence":"additional","affiliation":[{"name":"Aichi Cancer Center Hospital  Nagoya Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie\u2010Laure","family":"Casadebaig","sequence":"additional","affiliation":[{"name":"Incyte International Biosciences S\u00e0rl  Morges Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazumi","family":"Suzukawa","sequence":"additional","affiliation":[{"name":"Incyte Biosciences Japan G.K  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8003-2584","authenticated-orcid":false,"given":"Kentaro","family":"Fukushima","sequence":"additional","affiliation":[{"name":"The University of Osaka Hospital  Suita Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,1,21]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.1805"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2115304"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005794"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102024\u2010198714"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116133"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.4820"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022018730"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804980"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00172"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1098375"},{"key":"e_1_2_13_13_1","unstructured":"V.ZanfagninandG.Mathur \u201cCAR T\u2010Cells Therapies: Opportunities and Challenges \u201daccessed August 18 2024 https:\/\/www.cap.org\/member\u2010resources\/articles\/car\u2010t\u2010cells\u2010therapies\u2010opportunities\u2010and\u2010challenges."},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1805104"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1470\u20102045(20)30441\u20101"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(21)00591\u2010X"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.3196_LBA4"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591\u2010021\u201001622\u20100"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352\u20103026(24)00166\u20102"},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000317"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008\u20105472.Can\u201008\u20102268"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1470\u20102045(20)30225\u20104"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.283480"},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023020637"},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2152\u20102650(21)01860\u20107"},{"key":"e_1_2_13_26_1","unstructured":"ClinicalTrials.gov \u201cA Study Evaluating Safety PK and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed\/Refractory Non Hodgkin Lymphoma (R\/R NHL) or Chronic Lymphocytic Leukemia (CLL) (topMIND) \u201d(2024)."},{"key":"e_1_2_13_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102024\u2010212970"},{"key":"e_1_2_13_28_1","volume-title":"MONJUVI. Prescribing Information","author":"US FDA","year":"2021"},{"key":"e_1_2_13_29_1","unstructured":"EMA \u201cMinjuvi. Summary of Product Characteristics \u201d(2024) https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/minjuvi\u2010epar\u2010product\u2010information_en.pdf."},{"key":"e_1_2_13_30_1","unstructured":"US FDA \u201cMONJUVI. Prescribing Information \u201d(2025) https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/761163s013lbl.pdf."},{"key":"e_1_2_13_31_1","doi-asserted-by":"publisher","DOI":"10.1021\/acsmedchemlett.9b00334"},{"key":"e_1_2_13_32_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.120.265538"},{"key":"e_1_2_13_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102016\u201001\u2010643569"},{"key":"e_1_2_13_34_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2013.54.8800"},{"key":"e_1_2_13_35_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2006.09.2403"},{"key":"e_1_2_13_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/rssc.12089"},{"key":"e_1_2_13_37_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.20.01366"},{"key":"e_1_2_13_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2022.01.025"},{"key":"e_1_2_13_39_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.275958"},{"key":"e_1_2_13_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.15308"},{"key":"e_1_2_13_41_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045\u2010025\u201001702\u20105"}],"container-title":["Cancer Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cas.70306","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/cas.70306","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cas.70306","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T09:27:37Z","timestamp":1775122057000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/cas.70306"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,21]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1111\/cas.70306"],"URL":"https:\/\/doi.org\/10.1111\/cas.70306","archive":["Portico"],"relation":{},"ISSN":["1347-9032","1349-7006"],"issn-type":[{"value":"1347-9032","type":"print"},{"value":"1349-7006","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,21]]},"assertion":[{"value":"2025-08-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}